Articles related to HEAD & NECK CANCER (HNC)

Patients receiving pembrolizumab before, during, and after surgery demonstrated longer event-free survival and higher substantial tumor shrinkage rates, with median survival extending from 30.4 to 51.8 months compared to standard care alone.

The FDA’s recent approval of toripalimab, based on the JUPITER-02 and POLARIS-02 clinical trials, marks a significant milestone in the treatment of nasopharyngeal carcinoma. With a median progression-free survival of 11.7 months, toripalimab has shown promising results in improving patient outcomes.

Discover how a novel combination therapy targeting EGFR and AXL proteins could revolutionize the treatment of head and neck squamous cell carcinoma and lung adenocarcinoma.

Gain actionable insights into managing oral health complications in radiation therapy patients; a valuable course for any dental professional committed to multidisciplinary care.

Learn more about the alarming trend of diagnostic delays in head and neck cancer patients due to inappropriate antibiotic prescribing, and why adhering to current clinical guidelines is more crucial than ever.

The rise in oropharyngeal cancer rates, linked to high-risk HPV strains transmitted through oral sex, underscores the need for healthcare providers to promote safe sex practices, HPV vaccination, and early symptom recognition.